摘要
目的探讨垂体肿瘤转化基因(PTTG)、血管内皮细胞生长因子-C(VEGF-C)的表达以及表皮生长因子受体(EGFR)基因突变与非小细胞肺癌临床病理特征和预后之间的关系。方法回顾性选取2015年1月至2016年1月接收治疗的非小细胞肺癌患者100例作为研究对象,通过免疫组化和实时荧光定量PCR对患者PTTG及VEGF-C蛋白和mRNA的表达进行检测,结合预后和临床病理特征进行分析。结果 PTTG和VEGF-C的表达与患者的年龄、性别、吸烟情况、病理类型之间无相关性(P>0.05);PTTG和VEGF-C的表达在不同预后之间具有相关性(P<0.05);存活时间≤3年PTTG阳性率为77.4%,存活时间>3年阳性率为42.1%;存活时间≤3年VEGF-C阳性率为77.4%,存活时间>3年阳性率为44.7%。存活时间≤3年PTTG、VEGF-C阳性率明显高于存活时间>3年(P<0.05);EGFR基因突变和患者的年龄、吸烟情况之间无相关性(P>0.05);非小细胞癌女性患者的EGFR基因突变检出率为18.0%,高于男性的6.0%,腺癌EGFR基因突变检出率19.1%高于鳞癌的6.7%,同时高于大细胞癌的0.0%,存活时间≤3年的EGFR基因突变检出率1.6%低于存活时间>3年的28.9%(P<0.05)。结论 PTTG、VEGF-C的表达能够促形成肿瘤微淋巴管,从而促使肿瘤细胞淋巴结发生转移;EGFR基因突变更多见于腺癌,PTTG、VEGF-C的表达和EGFR基因突变可以用作判断患者预后的指标。
Objective To analyze the clinical correlation of PTTG and VEGF-C expression and epidermal growth factor receptor(EGFR)gene mutation with the pathological features and clinical prognosis for NSCLC(non-small cell lung cancer)patients.Methods From January 2015 to January 2016,100 cases of non-small cell lung cancer patients were selected as the research objects.The expression of PTTG and VEGF-C in patients with protein and mRNA were detected by immunohistochemistry and real-time fluorescence quantitative PCR.The prognosis and the clinical and pathological features were analyzed.Results The differences between PTTG and VEGF-C expression with age,gender,smoking,pathological types were not significant(P>0.05).The differences between expression and prognosis in treatment of PTTG and VEGF-C were significant(P<0.05).PTTG positive rate was 77.4%in cases with survival time≤3 years,42.1%in cases more than 3 years.VEGF-C positive rate was 77.4%in cases with survival time≤3 years,44.7%in cases more than 3 years(P<0.05).The difference between EGFR gene mutation and the patient's age,smoking were not significant(P>0.05).EGFR mutation detection rate of female patients with non-small cell carcinoma was 18%,which was higher than the male 6%.EGFR mutation detection rate of adenocarcinoma was 19.1%higher than that of squamous cell carcinoma 6.7%and large cell carcinoma 0%.EGFR gene mutation detection rate in cases of less than 3 years was 1.6%lower than that more than 3 years 28.9%(P<0.05).Conclusion The expressions of PTTG and VEGF-C can promote the formation of lymphatic microvessel and the lymph node metastasis of tumor cells.The EGFR gene mutation is commonly seen for the patients with adenocarcinoma;the PTTG and VEGF-C expressions and the EGFR gene mutation can be considered as the indicators of the patient's clinical prognosis.
作者
顾磊
文斐
肖婕
GU Lei;WEN Fei;XIAO Jie(Department of Pathology,Huangshi Central Hospital of Edong Healthcare,Huangshi Hubei 435000,China)
出处
《临床和实验医学杂志》
2018年第7期739-743,共5页
Journal of Clinical and Experimental Medicine